Active	Status	Sponsor type	Region	Phase	Filter
9 Active 0 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tamhankar, Madhura
UplighTED, NCT06307613: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease	Recruiting	3	108	Europe, US, RoW	Efgartigimod PH20 SC, Placebo PH20 SC	argenx	Thyroid Eye Disease	02/26	10/27
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25
Aleman, Tomas
NCT05616793: Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)	Recruiting	1/2	15	US	AAV8.hLCA5	Opus Genetics, Inc, University of Pennsylvania	LCA5	12/24	01/28
LIGHTHOUSE, NCT05878860: ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis	Recruiting	1/2	21	US	ATSN-201	Atsena Therapeutics Inc.	X-linked Retinoschisis	10/25	10/29
Utz, Megan
No trials found